Market closed
BeiGene, Ltd/$ONC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Ticker
$ONC
Sector
Trading on
Industry
Biotechnology
Headquarters
Camana Bay, Cayman Islands
Employees
11,000
Website
BeiGene, Ltd Metrics
BasicAdvanced
$27B
-
-$6.12
0.64
-
Price and volume
Market cap
$27B
Beta
0.64
52-week high
$287.88
52-week low
$174.74
Average daily volume
532K
Financial strength
Current ratio
1.802
Quick ratio
1.506
Long term debt to equity
6.325
Total debt to equity
32.407
Interest coverage (TTM)
-38.61%
Management effectiveness
Return on assets (TTM)
-6.07%
Return on equity (TTM)
-18.77%
Valuation
Price to revenue (TTM)
7.035
Price to book
8.15
Price to tangible book (TTM)
8.28
Price to free cash flow (TTM)
-40.019
Growth
Revenue change (TTM)
54.96%
Earnings per share change (TTM)
-27.50%
3-year revenue growth (CAGR)
47.96%
3-year earnings per share growth (CAGR)
-26.95%
BeiGene, Ltd News
AllArticlesVideos
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
Benzinga·1 week ago
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
Business Wire·1 week ago
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
Seeking Alpha·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $27B as of March 14, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of March 14, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of March 14, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.64. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.